you have the possibility of mental retardation as the risk using animal antibodies is greater. YOU are an idiot.................................. rejection of intelligence is happening inside your brain. Every thing you put in your body caries risk. the air you breath right now caries risk. How many times have you posted this? How many times have you been called an idiot answer please!
If you look at the treatment blood purification is being done. ZMAPP and this could be standard care one day for different viruses. These companies could develop into major players. IBIOs Platform could be used to make many plantibodies now that are using animal based cures. The recovery could be aided with Hemopurifier.................
I have averaged down a few times and started adding AEMD also. They have another treatment that could get attention soon. Between these two spec stocks a guy could hit the ball out of the park in 2015...... “Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.
Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access “emergency use” provisions in the United States. Expanded access “emergency use” of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.”
Important: Aethlon will announce the results of its Medanta Medecity HCV Study which utilized Hemopurifier therapy on patients with Hepatitis C (HEP C) in various Genotypes. There are currently over 3 Million Hep C cases in the United States and over 170 Million worldwide. It is important to remember that Hep C is but one of dozens of indications which may be treated by the Hemopurifier
Buffet gave the Gates foundation 2 billion dollars. I could see Gates backing other EBOLA treatments like this.
SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. The device is a leading broad-spectrum treatment countermeasure against viral pathogens that are not treatable with drug or vaccine therapies. In HCV care, the device is positioned to address antiviral drug resistance and hard-to-treat patients who are unable to tolerate normally administered doses of antiviral drugs or peginterferon+ribavirin (PR) therapy. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients. LAUNCH _ - Aethlon is now preparing to launch the first U.S. clinical Hemopurifier® based on the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study, which will be conducted at the DaVita MedCenter Dialysis in Houston, Texas, will contribute safety data to support the advancement of Hemopurifier® therapy as a broad-spectrum countermeasure against bioterror and pandemic threats and chronic viral pathogens such as HIV and HCV. Hemopurifier® therapy is available to treat Ebola patients in the U.S. through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At the time Hemopurifier® therapy was administered to the Ugandan physician, he was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment.
Gates money could do it. The odds are slim of that happening ... It would help as Ebola is not on the front burner. The BARDA press will defiantly help. We should be trading higher as we are back where we started before Ebola.
The Bill & Melinda Gates Foundation, run by Microsoft Corporation’s (MSFT) founder Bill Gates and supported by Wellcome Trust and the US government, has stepped up to provide help in the grave situation. It recently announced that it will be looking for ways to help speed up ZMapp’s production.
ZMapp is an experimental drug developed by privately-held Mapp Biopharmaceutical Inc. It is a combination of three monoclonal antibodies that are produced using tobacco leaves. It generally takes months to get the drug ready for use.
ZMapp has been administered to several health workers, seven of which were foreign health aid officials working in West Africa. Kent Brantly, an American UN health official, was the first person who received it and then recovered from the deadly virus. Two of the seven patients given ZMapp died; however, others were cured successfully. The success rate makes it the most advanced experimental Ebola drug right now.
It came across the local news station that he gave GATES the money.... Its just for the general Bill and Melissa foundation...... I am sure some of the money will go into vaccines and disease cures... Not only Ebola but for many of their causes.
Warren Buffett donates USD 2.1 billion to charity, largest in 2014
PTI New Delhi Last Updated: December 10, 2014 | 17:22 IST
As a general rule big funds do not buy under 5 dollars. Many small cap and penny stock funds can buy. If you go to the Wallstreet Journal and put in a IBIO you will see many funds are adding IBIO regardless of what is normal.
These institutions and Funds own shares. Many have been adding the last two months. You know about Aspire and Eastern Capital. Vanguard Extended Market Index Fund, Vanguard Total Stock Market Index Fund Vanguard Total Stock Market Index Fund Fidelity Spartan Extended Market Index Fund Vanguard Invt. Fds. ICVC - US Equity Index
KCG Americas LLC
Northern Trust Investments, Inc.
G. W. Henssler & Associates Ltd.
Millennium Management LLC
SSgA Funds Management, Inc.
Thompson, Davis & Co.
UBS Financial Services, Inc.
Vanguard Group Inc.
991,217 $609 09/30/2014
IBIO 991,217 $609 09/30/2014
Geode Capital Management LLC
342,667 $210 09/30/2014
IBIO 342,667 $210 09/30/2014
KCG Holdings Inc.
97,702 $60 09/30/2014
IBIO 97,702 $60 09/30/2014
Northern Trust Corp
38,976 $24 09/30/2014
IBIO 38,976 $24 09/30/2014
GW Henssler & Associates Ltd.
17,500 $11 09/30/2014
IBIO 17,500 $11 09/30/2014
State Street Corp
13,400 $8 09/30/2014
IBIO 13,400 $8 09/30/2014
Thompson Davis & CO. Inc.
5,000 $3 09/30/2014
IBIO 5,000 $3 09/30/2014
Its hard not to know about IBIO if you have studies Ebola or small cap biotech stocks.
What about the MAPP, ICON licensing? Kentucky and Amgen? BARDA news and Caliber could come any day. Better wipe off the crystal ball as it is no good. They have a big pipeline and a host of vaccines that could bring news. JAZZ or GSK could even buy them for the monoclonal antibodies . They saw the great White house news. The Funding could double this with contracts. Then their is NOVICCi that Mapp contacted..... news could be from a number of places.
the Whites house fact sheets and Directors testimony was just a confirmation IBIO was on the right track. That should have been the buy signal for you. Now we are sitting on a billions being distributed into EBOLA. This will hit DARPA ,BARTA , WHO, and be a liquidity wind fall for experimental companies that are leading the PACK!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases.
In addition to reviewing IBIO-CFB03, senior management will provide the following information to shareholders at the meeting:
•Opportunities for vaccine and antibody products using the iBioLaunch platform. The efficiency and flexibility of iBioLaunch technology and the company's issued patent portfolio have attracted increasing commercial and scientific interest in light of serious challenges such as the Ebola virus disease outbreak in West Africa.
•Opportunities for iBio's subsidiary operations and business relationships in Brazil. The iBioLaunch-based recombinant yellow fever vaccine continues development with collaborators in Brazil. Management will discuss previously announced product candidates under review for potential development for the Brazilian market.
•Opportunities in Japan. iBio has extended business development activities into Japan in collaboration with Kanematsu Chemicals Corporation, and will discuss the company's general approach to developing opportunities in non-U.S. markets.
•Programs involving government and NGO sponsorship. Phase 1 clinical trials of a malaria transmission-blocking vaccine and a hookworm vaccine are underway, both of which are non-commercial products fully funded by third parties. These and potential new programs provide valuable data on medically important applications of iBio's proprietary technology.
Additionally, co announced several lead formulations are under evaluation for clinical development, and work necessary to file an investigational new drug application with the FDA is being conducted, a process the company expects to complete by mid-2015.
•iBio has determined that preclinical efficacy results and lack of significant toxicity in experiments conducted to date justify high priority advancement of the product into clinical trials. The serious unmet
ALL HANDS ONM DECK_____________ that is a double for the companies leading the fight . The companies designed for out breaks . The ones that have improved plantibodies through out the years just waiting for this opportunity................. BINGO!
we could be a day away from a double. GOOD chances on a massive run to make this the stock of the year..... Many BIOTECH stocks double and triple and this has been set up to do it again. This time it will hold the PPS as people realize this is a game changer and disruptive stock. BIG PHARMA must act and GET IN THE GAME we are ticking down right now.................